Phase 1 Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older
- People who have been diagnosed with a brain tumor, including brain metastases (cancer that has spread to the brain), any grade of glioma, or meningioma
- People who are already scheduled to have standard surgical removal of their brain tumor as part of their normal medical care
- People who are willing and able to give written consent to take part (or have a legal representative who can do so on their behalf)
Who may not be able to join:
- People under 18 years of age
- People who have a condition or health issue that, in the investigator's judgment, could put their safety at risk or affect the quality of the trial data
- People who have not been medically cleared to have surgery
- People who are unable to tolerate an MRI scan or a PET/CT scan
- Women who are pregnant or breastfeeding
- People whose kidney function test results fall outside acceptable levels set by the trial (confirm with trial site)
- People whose liver function test results — including bilirubin levels — fall outside acceptable levels set by the trial (confirm with trial site)
- People whose liver enzyme levels (AST and ALT) fall outside acceptable levels set by the trial, unless they have Gilbert's syndrome, in which case a higher threshold may apply (confirm with trial site)
- People whose albumin (a protein measured in the blood) level is below 2.5 mg/dL
- People who have a spleen that does not function properly, or who have had their spleen removed
- People who have any condition that would make it unsafe to receive gadolinium-based contrast agent (a dye used during MRI scans)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Robert M Prins, UCLA / Jonsson Comprehensive Cancer Center
Phone: 310-592-9091
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of adverse events; Zirconium (Zr)-89 crefmirlimab berdoxam uptake
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.